THE TAPE
FLGT · Medical Laboratories · $662.4M

Fulgent Genetics, Inc. Common Stock

$24.08▼ −2.37%
Last close
Relative strength
79RS
of 99, against every stock▲ +26 on the month
Powering up
Turning
−4.4%
six months against Medical Laboratories
52-week range
−22.4%
from the high
$13.46$31.04
Setup
bull flagforming
−6.4%
against the pivot at $25.73
No report date on the calendar.
Growth FLATProof PENDING
Quarter to Sep 30, revenue +8% on a year ago
11/16 O 24.47 H 24.47 L 23.88 Vol 267.1K
Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year

All four are in order, fastest above slowest — every timeframe pointing the same way.

RS79
vs pivot−6.43%
Tightening—
Dry-up—
Up/down vol0.09
From high22%
squatfailed pokeforming4 of 7checks
Previous breakout still open ▲ +1.41% in Nov
Powering up
Support and resistance
Support below
$21.72
-9.8% · tested 5× · last 11 sessions ago
Resistance above
None within the last 120 sessions

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

The base has run 0.6 weeks and fell 7% from its ceiling at its deepest. The pivot is $25.73, and the stock closed 6.4% below it. Its relative strength rating is 79.

Against its industry
TurningBehind its industry over six months, but ahead over one and three.
One month against its industry
+18.7%
Three months against its industry
+15.0%
Six months against its industry
-4.4%

Read against an equal-weighted index of Medical Laboratories, which is +58.5% against the S&P 500 over six months Fully aligned.

Peers
Same theme
No themes — common and fine.
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 15.5% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$330.3M
+7.5% year on year
Operating margin
-39.2%
gross 33.8%
Net margin
-27.5%
Free cash flow
$-1.4M
-0.2% of market cap
Price to sales
2.01×
Price to earnings
—
not meaningful on a loss

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Nov 5
Key takeaway
Margins are improving, but the financial turnaround is not yet proven.
Revenue
$90.4M
+5.9% QoQ · +7.5% YoY
Gross margin
35.3%
+5.2 pts QoQ
Net income
−$13.2M
Loss
Free cash flow
$107.4M
Cash generating

What the numbers say

  • Revenue +7.5% year over year, +5.9% on the quarter
  • Good: Gross margin 35.3%, +5.2 points on the quarter
  • Weak: Net loss $13M, narrower than $30M last quarter
  • Good: Cash generating: operating cash flow $109M, free cash flow $107M
  • Good: Share count -10.0% in a year: buying back
  • Good: Net cash $87M · cash $87M
Revenue by quarter
Free cash flow
Net income
shares -10.0% in a year · net cash $86.8M

What is not obvious

  • Weak: Interest $7K a quarter against an operating loss: the debt is carried by the balance sheet, not operations

The desk’s own read

Flagged as drifting up since the report

Final read
Growth: FLAT · Economic proof: PENDING
Key question: Can the recovery in margins reach operating profit and cash?
The next test is operating profit: net loss $13M, narrower than $30M last quarter.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

Held by 1 of 46 tracked funds at the end of Q3 2026.

Last quarter: 1 added.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
GappedTape · 2026-11-10
+10.2%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Unusual volumeTape · 2026-11-10
3.9 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.
GappedTape · 2026-11-07
+27.2%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Moved 5%+ up on earningsTape · 2026-11-07
+27.2% on earnings 2026-11-05
No measurable effect: stocks behave like random ones over the next three sessions (604 cases over 42 nights).
Unusual volumeTape · 2026-11-07
10.1 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.
Reported resultsFiling · 2026-11-06
2.02
No measurable effect: stocks behave like random ones over the next three sessions (2,340 cases over 54 nights).
GappedTape · 2026-11-06
-5.2%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Earnings comingEvent · 2026-11-04
reports 2026-11-05 amc
No measurable effect: stocks behave like random ones over the next three sessions (2,970 cases over 40 nights).

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Fulgent Genetics, Inc. (FLGT) Reports Q3 Loss, Beats Revenue EstimatesZacks Investment Research · 12 days ago

Headlines link to the publisher. We do not host, summarise or rank them, and a headline appearing here is not a view about the company.

Insiders
Bought on the open market
0
Sold on the open market
8
$223,475 total

Sold: Gao Hanlin, Xie Jian.

Not counted above: 14 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-10-26 Gao Hanlin · Chief Scientific Officerwithheld for tax1,645$33,262
2026-10-26 Xie Jian · President and COOwithheld for tax4,361$88,179
2026-10-26 Kim Paul · CFO and Treasurerwithheld for tax2,748$55,565
2026-09-02 Gao Hanlin · Chief Scientific Officersell1,673$32,885
2026-09-02 Xie Jian · President and COOsell2,127$41,809
2026-09-01 Kim Paul · CFO and Treasurerwithheld for tax2,087$40,884
2026-09-01 Hsieh Ming · Chief Executive Officer, Director, 10% ownerwithheld for tax4,392$86,039
2026-08-27 Xie Jian · President and COOsell1,193$23,747

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

The geometry
Level · ceiling$25.73
The pole · over 4 sessions+37.7%
Through to the apex54%
Touches · swing points the lines are drawn through3 up · 3 down
Length0.6 weeks
What lines up

4 of 7 published checks currently line up. This is a count, not a probability — nothing on this site measures how often a setup works.

Relative strength of 80 or better
Above its 50-day line
Above its 200-day line
Averages fully stacked
Within 5% of its pivot
More up-volume than down-volume
Within 15% of its 52-week high

2 checks are not listed because this stock has too little history to judge them — a 200-day average needs 200 sessions. They are left out of the total rather than counted as failures.

What analysts expect
Strong buy0
Buy0
Hold1
Sell0
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray
5w · 19%

The most recent of 3 completed bases.

Checking your subscription…

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
Fulgent Genetics, Inc. Common Stock (FLGT) — The Tape